Company intelligence / Profile preview
Scilex Holding
Palo Alto, California, United Statesscilexholding.com ↗
- Ownership
- Public · SCLX
- Development stage
- Other
01
Overview
Scilex has three FDA-approved products (ZTlido®, Elyxyb®, Gloperba®), spanning topical and oral non-opioid pain relief; key pipeline assets (SP-102, SP-103, SP-104) are advancing, with SP-102 meeting Phase 3 endpoints and SP-103 and SP-104 in Phase 2 and Phase 1/2, respectively[2][4][5][7].
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Small moleculeDeviceGel formulationTopical systemDelayed-release capsule
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
IPMC Company/Bio Innovation Consortium/NeuroBiogen Company (MAO-B inhibitor JV)Datavault (strategic investment for blockchain/RWA in biotech)
04
Financials
- Market cap
- $12M
- Total revenue
- $30.3M
- Enterprise value
- $106.9M
Beyond the preview
Go deeper on Scilex Holding.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scilex Holding.